Compare HOYA Corp. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 20.17%
- Company has very low debt and has enough cash to service the debt requirements
2
With a growth in Net Profit of 65.25%, the company declared Very Positive results in Dec 25
3
With ROE of 21.20%, it has a attractive valuation with a 5.84 Price to Book Value
4
Majority shareholders : FIIs
5
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 8,689,580 Million (Large Cap)
28.00
NA
0.00%
-0.55
21.32%
8.64
Revenue and Profits:
Net Sales:
244,720 Million
(Quarterly Results - Dec 2025)
Net Profit:
91,176 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.94%
0%
17.94%
6 Months
34.64%
0%
34.64%
1 Year
60.65%
0%
60.65%
2 Years
43.51%
0%
43.51%
3 Years
102.47%
0%
102.47%
4 Years
98.14%
0%
98.14%
5 Years
122.94%
0%
122.94%
HOYA Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.48%
EBIT Growth (5y)
11.35%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.51
Sales to Capital Employed (avg)
0.82
Tax Ratio
22.43%
Dividend Payout Ratio
27.52%
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
48.78%
ROE (avg)
20.17%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
5.84
EV to EBIT
20.83
EV to EBITDA
17.43
EV to Capital Employed
10.88
EV to Sales
6.00
PEG Ratio
2.57
Dividend Yield
0.00%
ROCE (Latest)
52.24%
ROE (Latest)
21.20%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 4 Foreign Institutions (0.06%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
244,720.00
234,493.00
4.36%
Operating Profit (PBDIT) excl Other Income
88,025.00
81,977.00
7.38%
Interest
497.00
500.00
-0.60%
Exceptional Items
-514.00
-179.00
-187.15%
Consolidate Net Profit
91,176.00
54,962.00
65.89%
Operating Profit Margin (Excl OI)
297.90%
289.90%
0.80%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 4.36% vs 6.39% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 65.89% vs 6.93% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
866,032.00
762,610.00
13.56%
Operating Profit (PBDIT) excl Other Income
392,211.00
343,856.00
14.06%
Interest
1,326.00
1,079.00
22.89%
Exceptional Items
-4,733.00
-7,412.00
36.14%
Consolidate Net Profit
201,750.00
182,566.00
10.51%
Operating Profit Margin (Excl OI)
396.80%
389.00%
0.78%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 13.56% vs 5.39% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 10.51% vs 8.16% in Mar 2024
About HOYA Corp. 
HOYA Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






